drugset / Trial / NCT03015922
Viral Immunotherapy in Relapsed/Refractory Multiple Myeloma
Phase 1
Unknown
4 enrolled
University of Leeds
Celgene Corporation · collabMyeloma UK · collabOncolytics Biotech · collab
NaSingle-groupOpen-labelTreatment
Summary
This study will recruit patients currently receiving either lenalidomide or pomalidomide whose disease is relapsing. This is a dose escalation study and the aim is to determine the maximum tolerated dose (MTD) of REOLYSIN® that can be given in combination with lenalidomide or pomalidomide. The study will also investigate the safety, side effects and effectiveness of this treatment combination. Pomalidomide and lenalidomide will be evaluated separately as two separate groups.
Timeline
- Start
- 2017-06-05
- Primary completion
- 2021-09-01
- Completion
- 2021-10-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lenalidomide | Other / unclassified | 10 mg | Oral |
| Subject | Pelareorep | Other / unclassified | 3e+10 unknown | Intravenous |
| Subject | Pomalidomide | Other / unclassified | 1 mg | Oral |